Clinical Trials Browser

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00577629 2017-05-30

Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma

Phase 2 Completed

39 enrolled 11 charts

Lymphoid

Lymphoma, B-Cell

NCT00490009 2017-03-30

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

Phase 2 Completed

9 enrolled 10 charts

Lymphoid

Lymphoma

NCT00490490 2017-03-29

Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy

Phase 2 Terminated

8 enrolled 11 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT01389076 2017-01-30

Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

Phase 2 Terminated

22 enrolled 8 charts

Lymphoid

Lymphoma, Follicular

NCT00933335 2017-01-18

Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab

Phase 2 Completed

38 enrolled 36 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT00950755 2017-01-18

Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology

Phase 2 Completed

41 enrolled 25 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT00996996 2017-01-11

Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma

Phase 2 Completed

77 enrolled 34 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT01663714 2017-01-11

Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.

Phase 2 Completed

30 enrolled 25 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT00938041 2017-01-09

Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody

Phase 2 Completed

32 enrolled 11 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT01868035 2017-01-09

Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP

Phase 2 Completed

15 enrolled 18 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT00989664 2016-12-13

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma

Phase 2 Completed

60 enrolled 26 charts

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

NCT01224821 2016-12-12

RIT-II-001

Phase 2 Completed

47 enrolled 22 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT00996593 2016-11-23

Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab

Phase 2 Completed

43 enrolled 28 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT00107380 2016-03-07

S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Phase 2 Completed

86 enrolled 8 charts

Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT00073931 2015-02-05

Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2 Completed

25 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00003784 2013-01-24

S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 2 Completed

102 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia

NCT00240565 2012-08-13

Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma

Phase 2 Completed

93 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT00475332 2012-02-15

Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar

Phase 2 Terminated

2 enrolled 6 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT00022932 2005-06-24

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

Phase 2 Unknown

Lymphoid

Lymphoma, Non-Hodgkin

NCT00022945 2005-06-24

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

Phase 2 Completed

Lymphoid

Lymphoma, Mantle-Cell

Clinical Trials

Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma

Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma

A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy

Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab

Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology

Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma

Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.

Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody

Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma

RIT-II-001

Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab

S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma

Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma